• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The International journal of pharmacy practice >Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome
【24h】

Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome

机译：心肺贫血综合征患者促红细胞生成素使用的预测因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Objectives Chronic kidney disease ( CKD ) and anemia are common in patients with heart failure ( HF ) – these 3 conditions have been coined the C ardiorenal A nemia S ydrome ( CRAS ). The N ational K idney F oundation K idney D isease O utcomes Q uality I nitiative ( NKF‐K/DOQI ) guidelines do not specifically address patients with CRAS , creating uncertainty in erythropoietin ( EPO ) prescribing. We sought to determine predictors of EPO use in patients with CRAS . Methods We conducted a retrospective cohort study at the V eteran's A ffairs G reater L os A ngeles H ealthcare S ystem ( VAGLAHS ), a 300+ bed facility that provides primary and tertiary inpatient, and ambulatory care services, between J anuary 1, 2003 to D ecember 31, 2006. A multiple logistic regression model was constructed to identify predictors of EPO use among CRAS patients. Key findings Of 2058 patients with CRAS , 213 (10.3%) were prescribed EPO . There were significant differences in baseline characteristics between the EPO and non‐ EPO groups. The following predictors were found to be associated with EPO prescription: iron supplementation (odds ratio [ OR ] 52.70, 95% confidence interval [ CI ] 11.70–237.46), renal clinic appointment ( OR 2.60, 95% CI 1.79–3.76), malignancy ( OR 1.52, 95% CI 1.07–2.16) and use of hydralazine/nitrates ( OR 1.41, 95% CI 1.03–1.92). There was an inverse association found between EPO prescription and baseline hemoglobin ( OR 0.61, 95% CI 0.53–0.70) and eGFR ( OR 0.96, 95% CI 0.94–0.97). Conclusion A small proportion of patients eligible for EPO therapy according to guidelines at the time of the study were prescribed the indicated therapy. Markers of declining renal function or those suggesting need for anemia therapy were identified as EPO predictors.
机译：摘要目标慢性肾脏疾病（CKD）和贫血在心力衰竭（HF）患者中是常见的 - 这3条病症已被造成Nemia S ydrome（CRAs）。 N Ational K idney f盎司K idney d不良机o utcomes q Uitality i nitiative（nkf-k / doqi）指南没有特别解决Cras患者，在促红细胞生成素（epo）处方产生不确定性。我们试图确定Cras患者EPO使用的预测因素。方法我们在VETERAN的FFAIRS GREATER L OS中进行了回顾性队列研究，NGELES H ElealeCare S Ystem（Vaglahs），提供了300+卧床设施，为2003年1月1日之间提供了主要和三级住院生和外国护理服务。埃9月31日至2006年。建立了多个逻辑回归模型，以识别CRAs患者EPO使用的预测因子。 4258例CRAs患者的主要结果，213患者（10.3％）被规定了EPO。 EPO与非EPO组之间的基线特征存在显着差异。发现以下预测因子与EPO处方有关：铁补充剂（差距[或] 52.70,95％置信区间[CI] 11.70-237.46），肾病预约（或2.60,95％CI 1.79-3.76），恶性肿瘤（或1.52,95％CI 1.07-2.16）和使用氢氮嗪/硝酸盐（或1.41,95％CI 1.03-1.92）。在EPO处方和基线血红蛋白（或0.61,95％CI 0.53-0.70）和EGFR（或0.96,95％CI 0.94-0.97）之间存在反比结构。结论规定了一小部分符合研究指南的患者符合EPO疗法的患者，规定了指出的治疗。肾功能下降的标记或提示需要贫血治疗的人被确定为EPO预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号